Download Files:
Vincristine (sulfate)
$38 – $396
Products Details
Product Description
– Vincristine sulfate is an antitumor vinca alkaloid which inhibits microtubule formation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. It binds to microtubule with a Ki of 85 nM.
Web ID
– HY-N0488
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture and light)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C46H58N4O14S
Citations
– Acta Pharmacol Sin. 2021 Jan;42(1):108-114.|Am J Cancer Res. 2021 Apr 15;11(4):1428-1445.|bioRxiv. 2023 Jul 25.|bioRxiv. 2023 Jun 3.|bioRxiv. 2023 Sep 16.|Cancer Immunol Res. 2023 Mar 15;CIR-22-0483.|Cancers (Basel). 2021, 13(13), 3323.|Cell Chem Biol. 2020 Nov 19;27(11):1359-1370.e8.|Eur J Med Chem. 2018 Feb 25;146:157-170.|Front Microbiol. 2019 May 9;10:939. |Front Oncol. 2021 Apr 22;11:665763.|Front Oncol. 2021 Apr 6.|Hum Exp Toxicol. 2021 Feb 4;960327121991901.|Int J Biol Macromol. 2019 Jan 30;128:574-582.|Int J Nanomedicine. 2017 Mar 16;12:2081-2108.|J Chromatogr B. 2021, 122591.|Leuk Lymphoma. 2020 Feb;61(2):420-428.|Leukemia. 2021 Mar 29.|Mol Ther. 2021 Jul 1;S1525-0016(21)00353-1.|Neurobiol Learn Mem. 2019 Sep;163:107038.|Oncotarget. 2017 Dec 2;8(68):112313-112329.|Sci Adv. 2023 Feb 10;9(6):eade9238.|Sci Rep. 2019 Aug 12;9(1):11677.|Biochem Biophys Res Commun. 2023 Jun 27;674:27-35.|Biomed Pharmacother. 2020 May;125:110003.|bioRxiv. 2023 Apr 14.|bioRxiv. 2023 Feb 27.|bioRxiv. 2019 Dec.|Breast Cancer Res Treat. 2023 May 19.|Cancers (Basel). 2022 Oct 19;14(20):5127.|Cell Mol Immunol. 2023 Jan;20(1):51-64.|DRUG RESIST UPDATE. 2023 Feb 13;68:100951.|Front Oncol. 2020 Mar 13;10:308.|Front Pharmacol. 15 July 2022.|J Biomed Inform. 2023 May 15;104383.|J Transl Med. 2023 Jan 9;21(1):9.|Mol Pharm. 2022 Oct 21.
References
– [1]Jordan, M.A., et al. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res, 1985. 45(6): p. 2741-7.|[2]Donoso, J.A., et al, Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on axonal fibrillar organelles in vitro. Cancer Res, 1977. 37(5): p. 1401-7.|[3]Horton, J.K., et al. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol, 1988. 37(20): p. 3995-4000.|[4]Gidding, C.E., et al, Vincristine revisited. Crit Rev Oncol Hematol, 1999. 29(3): p. 267-87.|[5]Baguley, B.C., et al, Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer, 1991. 27(4): p. 482-7.|[6]Zhang D, et al. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine. 2017 Mar 16;12:2081-2108.
CAS Number
– 2068-78-2
Molecular Weight
– 923.04
Compound Purity
– 99.81
SMILES
– CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C4=CC([C@](C5=C6C7=CC=CC=C7N5)(C[C@](C[C@](CC)(O)C8)([H])C[N@@]8CC6)C(OC)=O)=C(OC)C=C4N9C=O)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O.O=S(O)(O)=O
Clinical Information
– Launched
Research Area
– Cancer
Solubility
– DMSO : 83.33 mg/mL (ultrasonic;warming;heat to 80°C)|H2O : 50 mg/mL (ultrasonic)
Target
– Apoptosis;Microtubule/Tubulin
Pathway
– Apoptosis;Cell Cycle/DNA Damage;Cytoskeleton
Product type
– Natural Products
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
